Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Metabolic Disease Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RICTOR drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RICTOR Recombinant Protein High purity (>90%), Endotoxin controlled. Sequence Verified. Theoretical MW optimized for interaction assays. |
View RICTOR Products |
| Gene Delivery | RICTOR Promise-ORF / Lentivirus Full-length ORF for stable cell lines to evaluate mTORC2 signaling. |
View RICTOR Products |
| Benchmark Ab | Anti-RICTOR Recombinant Antibody Recombinant positive control for immunoprecipitation and Western blot. |
View RICTOR Products |
| Validator | RICTOR siRNA Set For target knockdown verification and signaling specificity validation. |
View RICTOR Products |
| Related Target A | mTOR Core catalytic kinase subunit shared between mTORC1 and mTORC2 complexes. |
View mTOR Products |
| Related Target B | RAPTOR Regulatory-associated protein of mTOR, crucial for mTORC1-specific counter-screening. |
View RAPTOR Products |
| Related Target C | AKT1 Primary downstream substrate of mTORC2 (phosphorylated at Ser473). |
View AKT1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| mTORC2 Complex Assembly Reconstitution | Highly purified recombinant RICTOR with verified sequence integrity to support in vitro protein-protein interaction (PPI) assays. |
| mTORC1 vs. mTORC2 Selectivity Screening | Complete panel of recombinant RAPTOR and RICTOR proteins for comparative binding and counter-screening. |
| Lack of Controls | Clinical-grade benchmark antibodies and sequence-verified positive controls included. |
| False Positives in Phenotypic Assays | Validated siRNA pools included for target-specific knockdown verification. |
Live RICTOR R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for RICTOR therapeutics is intensifying, with major players shifting focus from traditional non-specific mTOR inhibitors to selective mTORC2 disruption. As first-generation dual mTORC1/2 inhibitors navigate the clinic, the next wave of R&D is targeting the RICTOR-mTOR interface directly using small molecules and PROTACs to avoid the metabolic toxicities associated with chronic mTORC1 inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule PPI Inhibitors | Academic Consortia, Biotech Startups | RICTOR-amplified Solid Tumors, SCLC | In vitro PPI Assay (Need high-purity recombinant RICTOR & mTOR) |
| PROTACs / Degraders | Preclinical Discovery Programs | Breast Cancer, Gastric Cancer | Target Degradation Kinetics (Need Lentivirus for stable reporter lines) |
| Antisense / RNAi | RNA Therapeutics Specialists | Advanced Malignancies | Knockdown Efficiency Validation (Need validated siRNA controls) |